luliconazole (Dosing, Interaction, Side Effect, Administration, Etc..)

DRUG CLASS:
Antifungal
Imidazole

DOSING:

Adult Dose

:
Tinea corporis:
Apply topically to affected skin and approximately 1 inch of the immediate surrounding area(s) once daily for 1 week

Tinea cruris:
Apply topically to affected skin and approximately 1 inch of the immediate surrounding area(s) once daily for 1 week

Tinea pedis:
Apply topically a thin layer to affected area(s) and approximately 1 inch of the immediate surrounding area(s) once daily for 2 weeks

Pediatric Dose

:
Tinea cruris:
(12 years or old)
Apply topically to affected skin and approximately 1 inch of the immediate surrounding area(s) once daily for 1 week

Tinea pedis:
(12 years or older)
Apply topically a thin layer to affected area(s) and approximately 1 inch of the immediate surrounding area(s) once daily for 2 weeks

INDICATIONS:
FDA-LABELED INDICATIONS:
Tinea Corporis
Tinea Cruris
Tinea Pedis

MECHANISM OF ACTION:

Luliconazole

is an azole antifungal that appears to inhibit the conversion of lanosterol to ergosterol (a component of fungal cell membranes) by inhibiting the enzyme lanosterol demethylase. Inhibition of the conversion of lanosterol to ergosterol causes accumulation of lanosterol and a decreased amount of ergosterol in fungal cell wall.

ADVERSE EFFECT:
Common:
Dermitologic:
Application Site reaction(less than 1%)

CONTRAINDICATION:
Specific Contraindication have not been Determined

DRUG INTERACTION:
The

potential of luliconazole

to inhibit cytochrome P-450 (CYP) enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 was evaluated in vitro. Based on in vitro assessment, luliconazole at

therapeutic doses

, particularly when applied to patients with moderate to severe tinea cruris, may inhibit the activity of CYP2C19 and CYP3A4. However, no in vivo drug interaction trials have been conducted to evaluate the effect of luliconazole on other drugs that are substrates of CYP2C19 and CYP3A4. Luliconazole is not expected to inhibit CYPs 1A2, 2C9 and 2D6 based on in vitro assessment. The induction potential of luliconazole on CYP enzymes has not been evaluated.

PHARMACOKINETICS:
Absorption:
Tmax Topical: 16.9 hours after

first dose

; 5.8 hours after final

dose

(tinea pedis)
21 hours after first dose; 6.5 hours after

final dose

(tinea cruris)

Distribution:
Protein Binding: greater than 99%

PREGNANCY CATEGORY:
Fetal Risk cannot be ruled out (TH)

BREAST FEEDING:
Infant risk cannot be ruled out

MONITORING:
Improvement in the signs or symptoms of interdigital tinea pedis; tinea cruris; or tinea corporis is indicative of efficacy

HOW TO TAKE OR ADMINISTRATION:
Topical:

Topical use

only; not for oral, ophthalmic, or intravaginal

use

DOSAGE FORM:
Topical

Cream

: 1%

PATIENT COUNSELING OR CLINICAL TEACHING:
Side effects may include application site reactions
Advise patient that drug is not for oral; intravaginal; or

ophthalmic use

Disclaimer:
For the Registered Medical Practitioner Only. We are not recommended for self medication. self medication is may harmful for health. We are only information about medicine.